BMO Capital Markets Cuts Phreesia (NYSE:PHR) Price Target to $14.00

Phreesia (NYSE:PHR) had its target price decreased by BMO Capital Markets from $32.00 to $14.00 in a report issued on Tuesday morning,Benzinga reports. BMO Capital Markets currently has an outperform rating on the stock.

A number of other equities analysts also recently issued reports on the stock. Canaccord Genuity Group dropped their price objective on shares of Phreesia from $33.00 to $22.00 and set a “buy” rating on the stock in a report on Tuesday. Royal Bank Of Canada began coverage on shares of Phreesia in a research report on Friday, January 9th. They issued a “moderate buy” rating and a $26.00 price target on the stock. Truist Financial reiterated a “hold” rating and set a $11.00 price target (down from $24.00) on shares of Phreesia in a research note on Tuesday. Weiss Ratings reissued a “sell (e+)” rating on shares of Phreesia in a research report on Wednesday, January 28th. Finally, Citigroup restated a “neutral” rating and issued a $10.00 price objective (down from $25.00) on shares of Phreesia in a research note on Tuesday. Twelve investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $22.00.

Phreesia Stock Down 0.6%

Phreesia stock opened at $8.35 on Tuesday. Phreesia has a one year low of $7.77 and a one year high of $32.76. The stock has a fifty day moving average of $12.07 and a 200 day moving average of $17.44. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.44 and a current ratio of 2.44. The stock has a market cap of $503.18 million, a PE ratio of 278.20 and a beta of 0.86.

Phreesia (NYSE:PHR) last announced its earnings results on Monday, March 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.05). The firm had revenue of $127.07 million during the quarter, compared to analysts’ expectations of $126.75 million. Phreesia had a return on equity of 3.33% and a net margin of 0.48%.The company’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same period in the previous year, the business posted ($0.11) earnings per share. As a group, sell-side analysts predict that Phreesia will post -1.1 EPS for the current year.

Insider Activity at Phreesia

In other Phreesia news, CFO Balaji Gandhi sold 3,829 shares of Phreesia stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $11.26, for a total transaction of $43,114.54. Following the transaction, the chief financial officer owned 146,740 shares of the company’s stock, valued at $1,652,292.40. The trade was a 2.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Evan Roberts sold 6,268 shares of the company’s stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $16.36, for a total transaction of $102,544.48. Following the completion of the transaction, the insider owned 826,554 shares of the company’s stock, valued at approximately $13,522,423.44. The trade was a 0.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 70,358 shares of company stock worth $1,123,569 in the last 90 days. Insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Phreesia

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in shares of Phreesia by 8.3% in the third quarter. Vanguard Group Inc. now owns 5,704,786 shares of the company’s stock valued at $134,177,000 after acquiring an additional 437,462 shares in the last quarter. New York State Common Retirement Fund grew its position in shares of Phreesia by 727.1% during the third quarter. New York State Common Retirement Fund now owns 136,856 shares of the company’s stock worth $3,219,000 after purchasing an additional 120,309 shares in the last quarter. Squarepoint Ops LLC grew its position in shares of Phreesia by 243.6% during the second quarter. Squarepoint Ops LLC now owns 100,922 shares of the company’s stock worth $2,872,000 after purchasing an additional 71,553 shares in the last quarter. Greenhouse Funds LLLP raised its stake in Phreesia by 16.8% during the 3rd quarter. Greenhouse Funds LLLP now owns 3,882,527 shares of the company’s stock valued at $91,317,000 after purchasing an additional 557,265 shares during the period. Finally, Bessemer Group Inc. lifted its holdings in Phreesia by 1,065.9% in the 3rd quarter. Bessemer Group Inc. now owns 554,513 shares of the company’s stock worth $13,043,000 after purchasing an additional 506,954 shares in the last quarter. Hedge funds and other institutional investors own 92.10% of the company’s stock.

More Phreesia News

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Analyst take: a MarketBeat piece argues Phreesia may have hit a trough and is well‑positioned to regain growth and market share over time, suggesting upside if execution and demand stabilize. Phreesia Hits Bottom in Q1: Rebound Ahead, Timing Uncertain
• Neutral Sentiment: Several large firms have issued neutral/market‑perform ratings (Robert W. Baird, JPMorgan, Citigroup), signaling limited near‑term conviction rather than outright sell ratings. Phreesia (NYSE:PHR) Earns “Neutral” Rating from Robert W. Baird
• Neutral Sentiment: Citizens JMP reaffirmed a market‑perform view, reflecting tepid near‑term expectations from another sell‑side firm. Citizens JMP Market Perform Reaffirmed
• Neutral Sentiment: Investor comparison coverage contrasts Phreesia with peers (MSP Recovery), providing context but not a clear directional trigger. Phreesia and MSP Recovery Critical Contrast
• Negative Sentiment: Primary catalyst: Phreesia reported its first full‑year profit but issued lower FY2027 revenue guidance, prompting a sharp selloff as investors focused on the reduced top‑line outlook. Phreesia (PHR) Is Down 25.5% After First Full-Year Profit But Lower 2027 Revenue Guidance
• Negative Sentiment: Multiple analysts cut expectations and targets (Canaccord cut its price target to $22; Needham, Stephens and BMO issued more pessimistic views), increasing selling pressure and lowering implied valuation. Needham Lowers Expectations for Phreesia BMO Capital Markets Issues Pessimistic Forecast for Phreesia Needham & Company LLC Has Lowered Expectations for Phreesia
• Negative Sentiment: The stock hit a new one‑year low after the earnings/guide miss, a technical signal that can accelerate outflows from momentum and quant funds. Phreesia Reaches New 1-Year Low After Earnings Miss
• Negative Sentiment: Legal risk: a law firm announced an investigation into potential securities‑law violations tied to prior guidance comments, adding uncertainty and potential headline risk. Investors in Phreesia Warned of Potential Securities Fraud
• Negative Sentiment: Some outlets and analysts pulled recommendations or expressed disappointment in growth guidance, reinforcing negative sentiment. Phreesia’s growth guidance disappointed. We’re pulling our recommendation.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.